AU Patent

AU2025279598A1 — Methods of treating hfpef employing dapagliflozin and compositions comprising the same

Assigned to AstraZeneca AB · Expires 2026-01-15 · 0y expired

What this patent protects

Abstract: Methods for treating and/or preventing HFpEF and/or at least one disease, disorder, and/or condition associated therewith in patients by the use of dapagliflozin and compositions comprising the same are disclosed. Abstract: 20 25 27 95 98 09 D ec 2 02 5 A b s t r a c t …

USPTO Abstract

Abstract: Methods for treating and/or preventing HFpEF and/or at least one disease, disorder, and/or condition associated therewith in patients by the use of dapagliflozin and compositions comprising the same are disclosed. Abstract: 20 25 27 95 98 09 D ec 2 02 5 A b s t r a c t : 2 0 2 5 2 7 9 5 9 8 0 9 D e c 2 0 2 5

Drugs covered by this patent

Patent Metadata

Patent number
AU2025279598A1
Jurisdiction
AU
Classification
—
Expires
2026-01-15
Drug substance claim
No
Drug product claim
No
Assignee
AstraZeneca AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.